NewAmsterdam Pharma Co N.V. (NAMS) stock
NAMSNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as NAMSW
$19.74+0.35 (+1.81%)
Close on Nov 18, 2026Market cap $2.36BP/E –Yield –
NewAmsterdam Pharma operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
NewAmsterdam Pharma's operating income for the twelve months ending Jun 30, 2026 was -$244.41M. For fiscal 2025 it was -$225.68M. The highest annual figure on record is -$3.56M in fiscal 2022.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$225.68M | – |
| FY2024 | Dec 31, 2024 | -$176.29M | – |
| FY2023 | Dec 31, 2023 | -$182.97M | – |
| FY2022 | Dec 31, 2022 | -$3.56M | – |
| FY2021 | Dec 31, 2021 | -$34.98M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$64.86M | – |
| Q1 FY2026 | Mar 31, 2026 | -$58.42M | – |
| Q4 FY2025 | Dec 31, 2025 | -$65.98M | – |
| Q3 FY2025 | Sep 30, 2025 | -$55.14M | – |
| Q2 FY2025 | Jun 30, 2025 | -$35.64M | – |
| Q1 FY2025 | Mar 31, 2025 | -$68.93M | – |
| Q4 FY2024 | Dec 31, 2024 | -$43.23M | – |
| Q3 FY2024 | Sep 30, 2024 | -$25.00M | – |
| Q2 FY2024 | Jun 30, 2024 | -$52.58M | – |
| Q1 FY2024 | Mar 31, 2024 | -$55.48M | – |
| Q4 FY2023 | Dec 31, 2023 | -$51.07M | – |
| Q3 FY2023 | Sep 30, 2023 | -$49.56M | – |
| Q2 FY2023 | Jun 30, 2023 | -$42.48M | – |
| Q1 FY2023 | Mar 31, 2023 | -$39.85M | – |
See a number that looks wrong?